Kiora Pharmaceuticals (KPRX) Competitors $3.52 -0.15 (-4.09%) (As of 11/5/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends KPRX vs. TTPH, SRZN, VTVT, ACHL, CLNN, RLYB, DRRX, CARM, PRPH, and OKYOShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Tetraphase Pharmaceuticals (TTPH), Surrozen (SRZN), vTv Therapeutics (VTVT), Achilles Therapeutics (ACHL), Clene (CLNN), Rallybio (RLYB), DURECT (DRRX), Carisma Therapeutics (CARM), ProPhase Labs (PRPH), and OKYO Pharma (OKYO). These companies are all part of the "medical" sector. Kiora Pharmaceuticals vs. Tetraphase Pharmaceuticals Surrozen vTv Therapeutics Achilles Therapeutics Clene Rallybio DURECT Carisma Therapeutics ProPhase Labs OKYO Pharma Tetraphase Pharmaceuticals (NASDAQ:TTPH) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Do analysts rate TTPH or KPRX? Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 172.11%. Given Kiora Pharmaceuticals' higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Tetraphase Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tetraphase Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AKiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is TTPH or KPRX more profitable? Kiora Pharmaceuticals has a net margin of 0.00% compared to Tetraphase Pharmaceuticals' net margin of -798.18%. Kiora Pharmaceuticals' return on equity of 15.57% beat Tetraphase Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tetraphase Pharmaceuticals-798.18% -210.86% -121.73% Kiora Pharmaceuticals N/A 15.57%11.34% Which has more volatility & risk, TTPH or KPRX? Tetraphase Pharmaceuticals has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Does the MarketBeat Community favor TTPH or KPRX? Tetraphase Pharmaceuticals received 368 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. However, 72.73% of users gave Kiora Pharmaceuticals an outperform vote while only 67.13% of users gave Tetraphase Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTetraphase PharmaceuticalsOutperform Votes38467.13% Underperform Votes18832.87% Kiora PharmaceuticalsOutperform Votes1672.73% Underperform Votes627.27% Do institutionals and insiders believe in TTPH or KPRX? 42.3% of Tetraphase Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 5.7% of Tetraphase Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation and earnings, TTPH or KPRX? Kiora Pharmaceuticals has lower revenue, but higher earnings than Tetraphase Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTetraphase Pharmaceuticals$7.38M2.17-$70.08M-$22.85-0.10Kiora PharmaceuticalsN/AN/A-$12.51MN/AN/A Does the media refer more to TTPH or KPRX? In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Tetraphase Pharmaceuticals. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for Tetraphase Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.45 beat Tetraphase Pharmaceuticals' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Tetraphase Pharmaceuticals Neutral Kiora Pharmaceuticals Neutral SummaryKiora Pharmaceuticals beats Tetraphase Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.69M$7.03B$5.24B$8.52BDividend YieldN/A7.95%5.06%4.17%P/E RatioN/A5.5388.1712.58Price / SalesN/A398.681,681.6994.04Price / CashN/A22.2833.8731.42Price / Book0.515.694.754.58Net Income-$12.51M$152.35M$116.51M$224.55M7 Day Performance-4.55%-1.75%-0.83%-0.83%1 Month Performance6.37%14.51%5.48%2.97%1 Year Performance-34.15%37.44%33.91%25.23% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.781 of 5 stars$3.52-4.1%$10.00+184.1%-34.2%$10.45MN/A0.0010Gap DownTTPHTetraphase PharmaceuticalsN/A$2.20flatN/A+0.0%$15.98M$7.38M-0.12119SRZNSurrozen2.018 of 5 stars$11.88-10.2%N/A+84.6%$42.41M$12.50M0.0042News CoverageGap DownVTVTvTv TherapeuticsN/A$14.00-0.2%N/A-10.3%$42.23M$2.02M-2.049Gap DownACHLAchilles Therapeutics1.9588 of 5 stars$1.03flat$4.00+290.2%+18.7%$42.12MN/A-0.64250Upcoming EarningsCLNNClene3.3952 of 5 stars$5.67-7.2%$72.33+1,175.7%-29.8%$41.90M$650,000.00-1.27100RLYBRallybio3.1176 of 5 stars$1.02+1.0%$10.00+880.4%-75.4%$41.90MN/A-0.5740DRRXDURECT2.738 of 5 stars$1.35+0.7%$21.00+1,455.6%-50.5%$41.59M$8.55M-2.2180Upcoming EarningsAnalyst ForecastCARMCarisma Therapeutics2.587 of 5 stars$1.05+5.0%$7.00+566.7%-67.6%$41.54M$14.92M-0.5920News CoverageGap UpPRPHProPhase Labs3.0594 of 5 stars$2.19+2.3%$11.00+402.3%-51.8%$40.83M$44.38M-1.81130Positive NewsOKYOOKYO Pharma3.3516 of 5 stars$1.16-3.3%$7.00+503.4%-35.6%$40.60MN/A0.007 Related Companies and Tools Related Companies Tetraphase Pharmaceuticals Competitors Surrozen Competitors vTv Therapeutics Competitors Achilles Therapeutics Competitors Clene Competitors Rallybio Competitors DURECT Competitors Carisma Therapeutics Competitors ProPhase Labs Competitors OKYO Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPRX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.